Healthcare (Basel) 2021 Apr 1;9(4). Epub 2021 Apr 1.
Hallym University Medical Center, Hallym Institute of Translational Genomics and Bioinformatics, Anyang 14068, Gyeonggi-do, Korea.
Limited data are available on the diagnostic utility of circulating tumor DNA (ctDNA) in early-stage thyroid cancers for , , , and promoter mutations, which are known detectable markers for thyroid cancers. Here, we analyzed the above driver mutations in ctDNA and matched neoplastic tissues from patients with early-stage thyroid cancers in order to investigate diagnostic utility of circulating markers in distinguishing from other mimicking thyroid lesions and healthy individuals. In total, 73 matched neoplastic tissue and plasma samples [thyroid cancers (n = 62), benign thyroid disorders (n = 8), and parathyroid lesions (n = 3)] and 54 plasma samples from healthy individuals (as controls) were analyzed for , , , and promoter mutations using peptide nucleic acid clamp real-time PCR. Read More